# Study of Efficacy and Safety of LCZ696/Amlodipine in Grade 1 and 2 Hypertension Patients Uncontrolled by LCZ696 Monotherapy

Study · id `cardio:ct-nct06236061` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06236061](<https://clinicaltrials.gov/study/NCT06236061>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06236061

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 718 participants.

## Technical summary

Registry record NCT06236061. Randomized; triple masking; primary purpose treatment. Start 2024-04-08 (actual); primary completion 2025-05-28 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 718 participants (enrolled count; ClinicalTrials.gov record NCT06236061, source copy `cardio:ctgov-nct06236061-2026-01-13`, retrieved 2026-10-26)
- Started: 2024-04-08 (actual) (ClinicalTrials.gov record NCT06236061, source copy `cardio:ctgov-nct06236061-2026-01-13`, retrieved 2026-10-26)
- Primary completion: 2025-05-28 (actual) (ClinicalTrials.gov record NCT06236061, source copy `cardio:ctgov-nct06236061-2026-01-13`, retrieved 2026-10-26)
- Completion: 2025-12-23 (actual) (ClinicalTrials.gov record NCT06236061, source copy `cardio:ctgov-nct06236061-2026-01-13`, retrieved 2026-10-26)
- Countries: Japan (ClinicalTrials.gov record NCT06236061, source copy `cardio:ctgov-nct06236061-2026-01-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06236061-2026-01-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study of Efficacy and Safety of LCZ696/Amlodipine in Grade 1 and 2 Hypertension Patients Uncontrolled by LCZ696 Monotherapy
- Condition: Hypertension
- Intervention (Drug): LCZ
- Intervention (Drug): LCZ/AML 200 mg/2.5 mg
- Intervention (Drug): LCZ/AML 200 mg/5 mg
- Intervention (Drug): LCZ/AML 200 mg/10 mg
- Intervention (Other): Placebo
- Lead sponsor: Novartis Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Novartis (`cardio:novartis`)

## Provenance

Content hash: 0dc9e88f931ac6caee118ecebac9e1e88b795d2a0adbaad811807ef9e135cdd4
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
